These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. Marx PF; Hackeng TM; Dawson PE; Griffin JH; Meijers JC; Bouma BN J Biol Chem; 2000 Apr; 275(17):12410-5. PubMed ID: 10777524 [TBL] [Abstract][Full Text] [Related]
3. Role of zinc ions in activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Marx PF; Bouma BN; Meijers JC Biochemistry; 2002 Jan; 41(4):1211-6. PubMed ID: 11802720 [TBL] [Abstract][Full Text] [Related]
4. Kinetics of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)-catalyzed cleavage of C-terminal lysine residues of fibrin degradation products and removal of plasminogen-binding sites. Foley JH; Cook PF; Nesheim ME J Biol Chem; 2011 Jun; 286(22):19280-6. PubMed ID: 21467042 [TBL] [Abstract][Full Text] [Related]
5. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity. Zhou X; Weeks SD; Ameloot P; Callewaert N; Strelkov SV; Declerck PJ J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497 [TBL] [Abstract][Full Text] [Related]
6. Stimulation of thrombin- and plasmin-mediated activation of thrombin-activatable fibrinolysis inhibitor by anionic molecules. Plug T; Meijers JC Thromb Res; 2016 Oct; 146():7-14. PubMed ID: 27564657 [TBL] [Abstract][Full Text] [Related]
7. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis. Foley JH; Kim P; Nesheim ME J Biol Chem; 2008 Apr; 283(14):8863-7. PubMed ID: 18252711 [TBL] [Abstract][Full Text] [Related]
8. Insights into thrombin activatable fibrinolysis inhibitor function and regulation. Foley JH; Kim PY; Mutch NJ; Gils A J Thromb Haemost; 2013 Jun; 11 Suppl 1():306-15. PubMed ID: 23809134 [TBL] [Abstract][Full Text] [Related]
9. The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme? Marx PF; Plug T; Havik SR; Mörgelin M; Meijers JC J Thromb Haemost; 2009 Mar; 7(3):445-52. PubMed ID: 19054324 [TBL] [Abstract][Full Text] [Related]
10. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. Wang W; Boffa MB; Bajzar L; Walker JB; Nesheim ME J Biol Chem; 1998 Oct; 273(42):27176-81. PubMed ID: 9765237 [TBL] [Abstract][Full Text] [Related]
11. Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI)--a comparative study assessing the biological equivalence of rat, murine and human TAFI. Hillmayer K; Macovei A; Pauwels D; Compernolle G; Declerck PJ; Gils A J Thromb Haemost; 2006 Nov; 4(11):2470-7. PubMed ID: 17002650 [TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a. Semeraro F; Ammollo CT; Gils A; Declerck PJ; Colucci M J Thromb Haemost; 2013 Dec; 11(12):2137-47. PubMed ID: 24134522 [TBL] [Abstract][Full Text] [Related]
13. Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation. Zhou X; Declerck PJ J Thromb Haemost; 2015 Jun; 13(6):1084-9. PubMed ID: 25773535 [TBL] [Abstract][Full Text] [Related]
14. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets. Ni R; Neves MAD; Wu C; Cerroni SE; Flick MJ; Ni H; Weitz JI; Gross PL; Kim PY J Thromb Haemost; 2020 Sep; 18(9):2364-2376. PubMed ID: 32506822 [TBL] [Abstract][Full Text] [Related]
15. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis. Bazzi ZA; Lanoue D; El-Youssef M; Romagnuolo R; Tubman J; Cavallo-Medved D; Porter LA; Boffa MB BMC Cancer; 2016 May; 16():328. PubMed ID: 27221823 [TBL] [Abstract][Full Text] [Related]
16. Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment. Bazzi ZA; Balun J; Cavallo-Medved D; Porter LA; Boffa MB Clin Exp Metastasis; 2017 Feb; 34(2):155-169. PubMed ID: 28124276 [TBL] [Abstract][Full Text] [Related]
17. Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin. Schneider M; Brufatto N; Neill E; Nesheim M J Biol Chem; 2004 Apr; 279(14):13340-5. PubMed ID: 14715654 [TBL] [Abstract][Full Text] [Related]
18. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor. Marx PF; Havik SR; Marquart JA; Bouma BN; Meijers JC J Biol Chem; 2004 Feb; 279(8):6620-8. PubMed ID: 14660622 [TBL] [Abstract][Full Text] [Related]